Cellectricon and Censo Biotechnologies introduce a joint technology access program

High-quality Human iPSC-based discovery services for CNS and pain research.

Cellectricon AB and Censo Biotechnologies
Jan 25, 2017

Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.

The approach combines induced pluripotent stem cell-derived (iPSC-derived) cells, sourced and produced by Censo, with Cellectricon’s unique screening technologies, IP and expertise. The platform will enable high quality phenotypic screening of medium throughput libraries in customized human iPSC-derived diseased and healthy control models. Hits can be further evaluated in secondary/safety assays using human iPSC-derived cardiomyocytes and CNS neurons. This battery of human, functional assays will produce a highly refined short list of compounds ready for clinical testing.

“Differences in target composition and neuronal processing between humans and model organisms may lead to poor translation between animal studies and the clinical setting. By gaining access to human cells from virtually any disorder, our collaboration with Censo has significantly enhanced our discovery...

Censo’s CEO Aidan Courtney added, “There is an excellent alignment between Censo and Cellectricon. Our extensive expertise in the production of ethically approved human iPSCs and derivatives adds further value to Cellectricon’s proprietary discovery services. We are very excited that this program will enable clients to access highly relevant screening cascades.”

Interested in reading more?

Cellectricon and Censo Biotechnologies introduce a joint technology access program

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?